Last Updated on October 6, 2024 by The Health Master
The U.S. Food and Drug Administration (USFDA) has approved GSK Plc’s respiratory syncytial virus (RSV) vaccine, the British drugmaker said on Wednesday, making it the first shot to be cleared for protection against a common respiratory disease that can be fatal for older people.
The vaccine was approved for people aged 60 and older, the company said.
The approval makes GSK, which has been neck-and-neck with Pfizer in RSV vaccine development, the first company to tap into a multi-billion-dollar market and puts it ahead of rivals such as Moderna Inc and Bavarian Nordic .
Analysts have estimated the market for RSV vaccines to cross $10 billion by 2030.
GSK expects the vaccine to be available before the next RSV season in the United States, Chief Commercial Officer Luke Miels told Reuters on Wednesday before the approval.
He said the vaccine would be priced above $120 per shot provided the data from a study, which is expected soon, shows that it protects for two RSV seasons.
USFDA gives tentative nod for ARV oral, Dolutegravir
USFDA gives approval for next generation Pneumococcal Vaccine
USFDA gives approval for this ALS drug
USFDA gives nod for Nitrofurantoin Oral Suspension USP
USFDA gives approval for Icosapent Ethyl Capsules
National Medical Devices Policy 2023: Salient Features
Nitrosamine content high in some drugs
IPC invites laboratories to join Testing Programme for quality assurance
All Blood Centres / Banks to have NAT-PCR test by 2025
USFDA issues EIR to Indoco Remedies, Goa
Moving towards zero counterfeiting to ease traceability and authentication
Govt approves 5 Medical Devices Companies under PLI scheme
USFDA issues Form 483 with 3 observation to Zydus, Ahmedabad
Drug alert: 48 out of 1497 samples declared as NSQ in March 2023
Wet Granulation vs Dry Granulation: Understanding the Key Differences
